‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows
Amid the growing mayhem in parliament over the Brexit process, life science companies have been advised to continue preparing for the possibility that the UK might leave the EU without a deal at the end of next week.
You may also be interested in...
The UK health department says it has purchased ferry tickets that pharmaceutical companies can buy in order to transport their medicines and other product using alternative shipping routes between EU and UK ports in the event of a no-deal Brexit. It has also updated companies on how they can access additional warehousing space for medicine stockpiles.
New, more flexible regulatory approaches will be needed to deal with the integrated therapies coming through company pipelines, and the European Medicines Agency should play a “key orchestrating role” in smoothing the way, says Sabine Atzor, Roche’s head of EU regulatory policies.
If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies, could be tested on other kinds of products.